A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain

Endometriosis Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Elagolix Tablets in Patients With Moderate or Severe Endometriosis-associated Pain

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06076486
• Other study ID #: ALGKNP2022-III
• Status: Recruiting
• Phase: Phase 3
• Start date: September 14, 2023
• Est. completion date: September 30, 2026

Study information

• Verified date: September 2023
• Source: Nanjing Chia-tai Tianqing Pharmaceutical
• Contact: Yingfang Zhou
• Phone: 010-83572211
• Email: Zhouyf8853[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase 3, multicenter, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of elagolix tablets versus placebo in premenopausal women with moderate or severe endometriosis-associated pain.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 330
• Est. completion date: September 30, 2026
• Est. primary completion date: September 30, 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

1. Understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent.

2. Diagnosis of endometriosis by pathological diagnosis or surgery within 10 years prior to screening by laparoscopy or exploratory laparotomy; or diagnosis of endometriosis based on clinical presentation of endometriosis in combination with previous imaging studies according to Endometriosis Diagnosis and Treatment Guidelines (Third Edition).

3. Premenopausal female aged 18 and 49 years (both inclusive) with one complete menstruation prior to screening record in the diary for at least 35 days and at least one complete menstrual cycle before the first dosing.

4. Agree to take only protocol-specified permitted rescue analgesic medications during the screening and treatment Periods.

5. Cervical smear is normal or abnormal without clinical significance (acceptance of normal cervical smear within 6 months prior to screening; or participant is virgin and decides not to take cervical smear); ASCUS may be combined with HPV testing. ASCUS participants may be included if they are negative for high-risk HPV.

6. Agree to use non-hormonal contraception from signing the informed consent through 1 month after last dosing.

Exclusion Criteria:

1. Subjects with a history of sensitivity to elagolix or excipients; or with a known history of serious, life-threatening or significant allergy to any drug.

2. Previous non-responders to GnRH agonist or GnRH antagonist therapy as judged by the investigator.

3. Subjects with a history of previous or existing osteoporosis or other metabolic bone disease; or previous abnormal clinically significant hypocalcemia, hypophosphatemia or hyperphosphatemia; or DXA Z score (subjects < 40 years old) or T score (subjects = 40 years old) of lumbar spine (L1-L4), femoral neck or total hip BMD is < -2.0;

4. Subjects with unstable diseases (such as poorly controlled diabetes, poorly controlled hypertension, poorly controlled seizures, unstable angina pectoris, inflammatory bowel disease, hyperprolactinemia, malignant tumors (except basal cell carcinoma of the skin) or severe infection, etc.) unuitable for the study at screening as judged by the investigators;

5. Subjects with a history of hysterectomy, oophorectomy, or surgery affecting drug absorption; or those who plan to undergo the above surgery during the trial;

6. Subjects with a history of major depressive disorder or post-traumatic stress disorder within 2 years prior to screening or other major psychiatric disorder at any time (e.g., schizophrenia, bipolar disorder); or history of suicidal behavior or suicidality; or suicidality as judged by the investigators;

7. Subjects with undiagnosed vaginal and/or uterine bleeding within 3 months prior to screening;

8. Subjects with other chronic pain syndromes requiring chronic analgesia or other long-term treatment that would be expected to interfere with the assessment of endometriosis-related pain;

9. Subjects with a history of drug or alcohol abuse within 6 months prior to screening;

10. Subjects aged = 40 years with abnormal results of breast ultrasonography during the screening period or within 1 year prior to screening (BI-RADS classification grade 4 and above);

11. Clinically significant gynecological conditions (e.g., any non-malignant cyst > 6 cm, or malignant cyst) by TVU or transrectal ultrasound or transabdominal ultrasound at screening;

12. Subjects with hepatitis B [HbsAg is positive and detection of HBV-DNA indicates viral replication], hepatitis C [HCV antibody is positive and detection of HCV-RNA indicates viral replication], positive syphilis (except specific antibody detection positive, non-specific antibody detection negative and confirmed as inactive infection in combination with clinical judgment), known HIV positive history or HIV positive;

13. Subjects with moderate/severe liver injury caused by previous diseases, or AST or ALT or bilirubin = 2 × ULN at screening;

14. Subjects requiring the use of a prohibited long-acting anesthetic or immediate-release anesthetic for more than 2 consecutive weeks for the treatment of endometriosis-related pain within 6 months prior to screening;

15. Participation in any other interventional clinical trial (including drug and device clinical trials) within 1 month prior to screening;

16. Use of any systemic corticosteroids for more than 2 weeks within 3 months prior to screening or likely to require such therapy during the study (topical, inhaled, or nasal corticosteroids are allowed);

17. Use of GnRH agonists or GnRH antagonists (including participation in clinical trails of elagolix) within 6 months prior to screening; use of medroxyprogesterone acetate, danazol, aromatase inhibitors within 3 months prior to screening; use of oral contraceptives, or any hormonal treatment for endometriosis within 2 months prior to screening; use of Chinese herbal medicine for endometriosis treatment or symptom relief within 1 month prior to screening;

18. Subjects with IUD or subcutaneous contraceptive implants (the IUD or subcutaneous contraceptive implants removed more than 30 days prior to screening is allowed);

19. Subjects taking moderate or strong CYP450 3A inducers or OATP1B1 inhibitors within 1 month prior to the first dosing;

20. Pregnant or lactating women; or plan to have children during the trial (from signing the informed consent form to 3 months after using the study drug); or < 6 months after delivery; or < 3 months after abortion; or have a positive pregnancy test result during the screening period or on the day of randomization;

21. Subjects with increasing risk associated with the study, interference with the interpretation of study results, or inappropriate as judged by the investigators.

Related Conditions & MeSH terms

• Endometriosis

Intervention

Drug:
• Elagolix
Elagolix 200 mg tablets administered orally BID
• Elagolix placebo
Elagolix placebo administered orally BID

Locations

Country	Name	City	State
China	Peking University First Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing Chia-tai Tianqing Pharmaceutical

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of responders of dysmenorrhea (DYS) at week 12	The responder was defined as reaching a pre-defined threshold.	12 weeks
Primary	Percentage of responders of Non-Menstrual Pelvic Pain (NMPP) at week 12	The responder was defined as reaching a pre-defined threshold.	12 weeks
Secondary	Change from baseline in DYS	The DYS pain scale s range from 0 (none) to 3 (severe).	Through study completion, an average of 24 weeks
Secondary	Change from baseline in NMPP	The NMPP pain scales range from 0 (none) to 3 (severe).	Through study completion, an average of 24 weeks
Secondary	Change from baseline in Dyspareunia (DYSP)	The DYSP pain scales range from 0 (none) to 3 (severe).	Through study completion, an average of 24 weeks
Secondary	Change from baseline in Numeric Rating Scale (NRS) scores	The NRS pain scores ranges 0 (none) to 10 (worst pain ever).	Through study completion, an average of 24 weeks
Secondary	Change from baseline in rescue analgesic use	Use of rescue analgesic medications taken for endometriosis-associated pain was recorded by the subject daily as the total number of pills/tablets of each type taken within a 24-hour period.	Through study completion, an average of 24 weeks
Secondary	Percentage of participants with a Patient Global Impression of Change (PGIC) response	PGIC response was defined as very much improved and much improved selected by the subject to assess the change in endometriosis-associated pain since the initiation of study drug.	Through study completion, an average of 24 weeks
Secondary	Safety Specifications in the Treatment Period	AEs and SAEs occurred during the treatment period.	Through study completion, an average of 24 weeks